Goldman Sachs
CUE icon

Goldman Sachs’s Cue Biopharma CUE Stock Holding History

Goldman Sachs’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.85K Buy
1,138
+659
+138% +$6.15K ﹤0.01% 6390
2025
Q4 		$4.39K Sell
479
-1
-0.2% -$18 ﹤0.01% 6386
2025
Q3 		$10.3K Buy
480
+1
+0.2% +$23 ﹤0.01% 6257
2025
Q2 		$9.81K Sell
479
-1
-0.2% -$21 ﹤0.01% 6004
2025
Q1 		$13.1K Sell
480
-671
-58% -$24.9K ﹤0.01% 5961
2024
Q4 		$37.6K Buy
1,151
+532
+86% +$20K ﹤0.01% 5855
2024
Q3 		$14.1K Sell
619
-8,260
-93% -$179K ﹤0.01% 5689
2024
Q2 		$330K Buy
8,879
+7,358
+484% +$364K ﹤0.01% 5051
2024
Q1 		$86.3K Sell
1,521
-423
-22% -$29.8K ﹤0.01% 5265
2023
Q4 		$154K Buy
1,944
+1,307
+205% +$93.4K ﹤0.01% 5222
2023
Q3 		$44K Buy
637
+50
+9% +$4.88K ﹤0.01% 5289
2023
Q2 		$64.3K Buy
587
+123
+27% +$14.5K ﹤0.01% 5433
2023
Q1 		$49.7K Sell
464
-6
-1% -$572 ﹤0.01% 5554
2022
Q4 		$40.1K Buy
470
+4
+0.9% +$366 ﹤0.01% 5621
2022
Q3 		$31K Sell
466
-4,541
-91% -$391K ﹤0.01% 5855
2022
Q2 		$374K Sell
5,007
-12
-0.2% -$1.4K ﹤0.01% 5282
2022
Q1 		$735K Sell
5,019
-62
-1% -$13.1K ﹤0.01% 5068
2021
Q4 		$1.72M Sell
5,081
-2,733
-35% -$1.06M ﹤0.01% 4375
2021
Q3 		$3.42M Sell
7,814
-5,341
-41% -$1.86M ﹤0.01% 3697
2021
Q2 		$4.6M Sell
13,155
-6,915
-34% -$2.68M ﹤0.01% 3413
2021
Q1 		$7.35M Buy
20,070
+2,958
+17% +$1.22M ﹤0.01% 2814
2020
Q4 		$6.42M Buy
17,112
+5,854
+52% +$2.34M ﹤0.01% 2824
2020
Q3 		$5.08M Buy
11,258
+239
+2% +$138K ﹤0.01% 2884
2020
Q2 		$8.1M Buy
11,019
+5,805
+111% +$4.21M ﹤0.01% 2423
2020
Q1 		$2.22M Buy
+5,214
New +$2.53M ﹤0.01% 3226
2018
Q3 		– Sell
-413
Closed -$147K – 5588
2018
Q2 		$147K Buy
+413
New +$164K ﹤0.01% 5095

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

Goldman Sachs's CUE Position: Q1 2026 in Review

Goldman Sachs increased its Cue Biopharma (CUE) stake by 138% in Q1 2026, buying an estimated $6.15K and bringing the position to 1,138 shares worth $7.85K. The position accounts for ﹤0.01% of the portfolio, ranked #6390.

Goldman Sachs first reported a position in CUE in Q2 2018 and has held it in 26 quarters since. The position peaked at $8.1M in Q2 2020. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Goldman Sachs held 1,138 shares of Cue Biopharma worth $7.85K as of Q1 2026.
  • Goldman Sachs bought 659 Cue Biopharma shares in Q1 2026, an estimated $6.15K.
  • Cue Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6390 holding.
  • Goldman Sachs first reported a position in Cue Biopharma in Q2 2018 and has held it in 26 quarters since.
  • Goldman Sachs's Cue Biopharma position peaked at $8.1M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.